OSE Immunotherapeutics SA (OSE)

Overview

OSE Immunotherapeutics SA is a pivotal player in the field of clinical-stage biotechnology, with a pronounced focus on the development of immunotherapies targeting immune-oncology and immune-inflammation. Operating both within French territories and internationally, it dedicates its efforts towards groundbreaking therapies for formidable diseases. Since its inception in 2012 and subsequent name change from OSE Pharma SA to OSE Immunotherapeutics SA in May 2016, the company has established a strong foothold with its headquarters in Nantes, France. A testament to its collaborative spirit, OSE Immunotherapeutics has forged strategic alliances with notable entities such as GERCOR, ARCAGY-GINECO, Foundation FoRT, Nantes University Hospital, Boehringer Ingelheim, MabSilico, CKD, Servier, Veloxis Pharmaceuticals, and Chong Kun Dang Pharmaceutical Corporation.

Products and Services

• Tedopi - Currently in Phase III clinical trials targeting non-small cell lung cancer, Tedopi also extends its potential treatment to pancreatic and ovarian cancer in Phase II clinical trials. This innovative approach represents a significant advancement in cancer treatment strategies.
• OSE-279 - At the Phase I/II clinical trial stage, OSE-279 is designated for patients bearing advanced solid tumors or lymphomas, showcasing OSE Immunotherapeutics' dedication to combating a wide range of cancers.
• OSE-127 - A humanized monoclonal antibody, OSE-127 is undergoing Phase II clinical trial aimed at treating ulcerative colitis and Sjögren's Syndrome, underlining the company's commitment to addressing complex immune-inflammation conditions.
• FR104 - In Phase I clinical trial, FR104 is being developed for rheumatoid arthritis treatment, leveraging immunotherapeutic advances for better management of autoimmune diseases.
• BI 765063 - Currently in Phase I clinical trial, BI 765063 is focused on treating solid tumors, further broadening OSE Immunotherapeutics' oncology portfolio.
• OSE-230 - An agonist antibody against ChemR23, OSE-230 embodies the company's efforts to resolve chronic inflammation, showcasing a novel approach to immunotherapy treatments.
• BiCKI - A bispecific checkpoint inhibitor platform that targets PD-1, BiCKI is designed to combat primary and secondary resistance mechanisms developed by cancers, marking a pivotal advance in immune-oncology.
• CLEC-1 - Focusing on immune-oncology, CLEC-1 represents a therapeutic target with identified monoclonal antibody antagonists, emphasizing OSE Immunotherapeutics' innovative strides in cancer therapy.